Interleukin

Psoriasis and vitiligo are 2 autoimmune conditions that can occur concurrently in patients. At present, no single systemic therapy has been identified to be effective in treating both the conditions. Recent advances in our understanding of the T helper (Th) 17 subset of Th cells suggests that interleukin (IL)-17 may play a key role in the pathogenesis of both vitiligo and psoriasis. We report a case of anatomically superimposed psoriatic plaques and vitiligo for which treatment with ixekizumab leads to resolution of psoriasis but did not improve the patient’s vitiligo. While IL-17 is highly effective in the treatment of psoriasis, it does not seem to be an effective treatment for vitiligo